Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Demetrios Kouzoukas, Former Director of the Center for Medicare and Principal Deputy .
Clover Health Investments, Corp.April 15, 2021 GMT
NASHVILLE, Tenn., April 15, 2021 (GLOBE NEWSWIRE) Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover”), an innovative technology company improving health outcomes for America’s seniors, today announced Demetrios L. Kouzakas has joined its Board of Directors and will serve as a member of the Audit Committee.
“Clover and the U.S. government have a shared mission of supporting the health of Medicare beneficiaries and making every tax dollar as impactful as possible,” said Chief Executive Officer Vivek Garipalli. “Demetrios is a significant addition to the Board. Having led the legal and regulatory affairs department of the Medicare division at UnitedHealth, he understands the opportunity and challenge of operating at scale. He has an
Uji Klinis Fase II Vaksin Nusantara Tanpa Persetujuan BPOM, Komisi IX Beri Dukungan
tribunnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tribunnews.com Daily Mail and Mail on Sunday newspapers.
By Niv Elis - 04/13/21 07:54 PM EDT
The House on Tuesday approved a bill that would put off automatic cuts to Medicare provider payments until the end of the year.
The bill passed with a strong bipartisan majority of 384-38.
Technically, the House vote comes nearly two weeks after the cuts were set to take effect, but the delay came with knowledge that action could be postponed until Congress returned from recess and passed the legislation.
ADVERTISEMENT
The automatic cuts were originally put into place by the 2011 Budget Control Act, which set up an annual 2 percent reduction in Medicare payments as one of its mechanisms for reducing the debt. Congress has never allowed the cuts to take place, however, voting to overturn them regularly over the past decade.
14 April 2021 14:40 Share in:
NUR-SULTAN. KAZINFORM â The subunit vaccine against COVID-19 developed by Kazakhstani scientists is ready for clinical trials, Kazinform correspondent reports. Related news
Vice-Minister of Education and Science Miras Daulenov, several COVID-19 vaccines are being developed at the Research Institute for Biological Safety Problems, including the subunit (recombinant) vaccine, which is ready to enter clinical trials. The trials will begin after the authorization of the Health Ministry.
According to him, the Institute is also working on a polyvalent vaccine, with the British and South African variants being closely studied for updating vaccines.
Notably, the Research Institute for Biological Safety Problems is developing five COVID-19 vaccines, including the inactive QazCOVID-in vaccine, two vector vaccines, an attenuated vaccine and a subunit vaccine.
Photo Credit: IANS
IANSLive
New York, April 14 (IANS) Updated results from an ongoing Phase 3 clinical trial in the US have shown Moderna s Covid-19 vaccine to be 90 per cent effective against all cases of the disease, and greater than 95 per cent against severe cases.
To get full access of the story, click here to subscribe to IANS News Service
© 2021 IANS India Private Limited. All Rights Reserved. The reproduction of the story/photograph in any form will be liable for legal action.
For news, views and gossips, follow IANS at Twitter.
Update: 14-April-2021
vimarsana © 2020. All Rights Reserved.